Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Colorectal Neoplasms × Alpelisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 HER2-positive Metastatic Breast Cancer 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma 1

Interventions

Cetuximab 39 Irinotecan 33 pembrolizumab 32 Oxaliplatin 32 Bevacizumab 32 Capecitabine 31 Fluorouracil 30 Leucovorin 29 Nivolumab 20 Gemcitabine 13 regorafenib 12 Cyclophosphamide 12 Folfox protocol 11 Cisplatin 10 Pemetrexed 9 Carboplatin 9 tislelizumab 8 Paclitaxel 8 IFL protocol 8 Panitumumab 7 130-nm albumin-bound paclitaxel 7 durvalumab 6 Ipilimumab 6 HMPL-013 6 Drug Therapy 6 irinotecan sucrosofate 5 Trifluridine 5 Specimen Handling 5 Interleukin-2 5 Everolimus 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04753203 2023-10-31

ALCAP

Korean Cancer Study Group

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡